Request FREE sample PDF
Pharmacy benefit management market
Amebocyte Lysate Market Report Overview
The global amebocyte lysate market size USD 562.97 million in 2022 & the market is expected to generate USD 1491 million by 2031, exhibiting a CAGR of 11.43% during the forecast period.
Bacterial endotoxin testing, commonly referred to as amebocyte lysate testing, is used to identify the presence and concentration of bacterial endotoxin in the environment. The Limulus polyphemus, an Atlantic horseshoe crab, is extremely sensitive to endotoxins, according to investigations on its blood clotting mechanism. Later, an endotoxin test was created by combining medication samples with blood clotting factors from amebocytes, where the endotoxin caused the sample to coagulate. Limulus amebocyte lysate (LAL) is an aqueous extract of blood cells (amoebocytes) from the Atlantic horseshoe crab Limulus polyphemus. In order to check for endotoxins in biological products, medical equipment, and injectable medications, LAL reagents are typically utilised. They are used in many other places as well, such renal dialysis centres. Compared to the gelation method, the limulus amoebocyte lysate (LAL) test using chromogenic substrate is quicker and more automated. The LAL (limulus amebocyte lysate) test, commonly known as a bacterial endotoxin test, is a critical step in pharmaceutical microbiology and is used to assess the level of bacterial endotoxins in pharmaceuticals and biological products. Gram-negative bacteria have lipopolysaccharides termed endotoxins in their cell walls, which are a subclass of pyrogen. Pyrogens are a class of substances that cause an increase in body temperature. If used in excess of a certain dose, they can be harmful or even fatal to humans.
COVID-19 Impact: COVID-19 Pandemic Crisis has hampered market expansion
Although the COVID-19 pandemic had a favourable effect on the market, it had a negative impact on the sales of routine testing kits, which are primarily used to screen for cancer, blood sugar, cardiac indicators, lipid profile, cholesterol, and other infectious diseases. To assist the testing requirements of their respective nations at the commencement of COVID-19, many governments have initiated a number of programmes during the COVID-19 crisis. For instance, the German federal government requires that businesses distribute free COVID-19 self-testing kits once a week to employees who are not working from home. This requirement took effect in April 2021.
Latest Trends
"High sensitivity and Rising Benefits Leading Market Expansion"
Amebocyte lysate tests are performed in a variety of biomedical institutions, including research institutes, production facilities for medical devices, and pharmaceutical firms. In order to stop the development of serious infections or unfavourable immunological reactions in a person, it is crucial to regulate and manage the amount of endotoxin or pyrogen in medications, particularly parenteral injectable and implanted devices. Additionally, the importance of amebocyte lysate in monitoring high-purity water, a crucial component in the production of biologicals, drugs and medications, and medical devices, has grown due to its high sensitivity in detecting endotoxin compared to other assays. Additionally, the amebocyte lysate test has been widely used in research and development studies to examine the effects of pyrogens and endotoxins on human health and the environment. These elements are anticipated to have a crucial role in the market's future revenue growth.
Amebocyte Lysate Market Segmentation
- By Type Analysis
According to type, the market can be segmented into Limulus Amebocyte Lysate, Tachypleus Amebocyte Lysate. Limulus Amebocyte Lysate is anticipated to be the leading segment.
- By Application Analysis
Based on application, the market can be divided into Drug Testing, Clinical Diagnosis, Other. Drug Testing will be the dominating segment.
Driving Factors
"Innovative Methods for Laboratory Testing will fuel The Market Growth"
TÜV SÜD announces its plans to enlarge its Medical and Health Services (MHS) facilities in New Brighton, Minnesota. The 20,000 square foot laboratory expansion to the 36,000 square foot testing facility will provide an end-to-end testing solution for all medical devices by June 2022. The state-of-the-art facility will provide a wide range of biological and chemical testing of medical equipment in addition to TÜV SÜD's current active medical device testing capabilities. TÜV SÜD will be able to finish testing of medical equipment and healthcare equipment even more swiftly with the additional component. The experts at TÜV SÜD will be able to provide customers the most modern solutions to meet the continuously evolving regulatory demands of the medical device sector as a result. This will accelerate market expansion.
"Increasing Infrastructure Spending for Healthcare will fuel The Market Growth"
The increase in healthcare spending, which contributes to the development of the market for limulus amebocyte lysate (LAL), is another important reason. The turbidimetric LAL test technique uses a photometric equipment to kinetically assess how cloudy (or turbid) the clotted test fluid is. This LAL variation, which yields quantitative data, is more appropriate than the gel-clot approach (LoD of 0.001 EU/ml) for endotoxin release testing of simple pharmaceutical items. The market dynamics will also be impacted by different government organisations' efforts to strengthen the healthcare infrastructure by boosting financing.
Restraining Factors
"Lacking Of Health Infrastructure Impedes Market Growth"
On the other hand, the government's strict guidelines on animal testing and the rising price of endotoxin detection devices may slow the market's expansion. The market for limulus amebocyte lysate (LAL) testing will face difficulties due to a shortage of qualified workers and inadequate healthcare infrastructure in developing nations.
Amebocyte Lysate Market Regional Insights
"North America Will Dominate the Market During Forecast Period"
The market for limulus amebocyte lysate (LAL) testing is dominated by North America as a result of growing government initiatives to support infectious disease-related research. Over the course of the forecast, North America is anticipated to have the largest revenue share in the global market. Demand for amebocyte lysate testing has increased as a result of the region's increased focus on developing cutting-edge and novel biotherapeutics and the rising danger of endotoxin contamination. Workflows for endotoxin testing have become more important in the pharmaceutical sector as a result of rising preferences for personalised medication and the quick advancement of drug development and research. Major businesses' presence, the region's well-established pharmaceutical sector, and rising investments in the development of cutting-edge biologics and medical devices are some of the main factors anticipated to drive the market's revenue growth.
Key Industry Players
"Key Players Focus on Partnerships to Gain a Competitive Advantage "
Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.
LIST OF TOP AMEBOCYTE LYSATE COMPANIES
- Zhanjiang Bokang Marine Biological Co. Ltd. (china)
- Zhanjiang A&C Biological Ltd. (China)
- Fuzhou Xinbei Biochemical Industrial Co., Ltd (China)
- Associates of Cape Cod (U.S.)
- Xiamen Bioendo Technology Co., Ltd. (China)
- LONZA (Switzerland)
- Charles River Laboratories (U.S.)
Report Coverage
This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, and restraints. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.
REPORT COVERAGE | DETAILS |
---|---|
Market Size Value In |
US$ 562.97 Million in 2022 |
Market Size Value By |
US$ 1491 Million by 2031 |
Growth Rate |
CAGR of 11.43% from 2022 to 2031 |
Forecast Period |
2022-2031 |
Base Year |
2023 |
Historical Data Available |
Yes |
Regional Scope |
Global |
Segments Covered | |
By Type
|
|
By Application
|
Frequently Asked Questions
-
What value is the amebocyte lysate market expected to touch by 2031?
The global amebocyte lysate market size is expected to reach USD 1491 million by 2031.
-
What CAGR is the amebocyte lysate market expected to exhibit by 2031?
The amebocyte lysate market is expected to exhibit a CAGR of 11.43% by 2031.
-
What are the key players in the amebocyte lysate market?
Zhanjiang Bokang Marine Biological Co. Ltd., Zhanjiang A&C Biological Ltd., Fuzhou Xinbei Biochemical Industrial Co., Ltd, Associates of Cape Cod, Xiamen Bioendo Technology Co., Ltd., LONZA, Charles River Laboratories are the key players in the amebocyte lysate market.
-
What are the key factors driving the amebocyte lysate market?
Key elements anticipated to propel amebocyte lysate market revenue growth over the forecast period include increasing adoption of amebocyte lysate testing for quality testing and assurance of pharmaceutical products like drugs and vaccines and increasing incorporation of endotoxin testing workflow in research and development activities in the biotechnology and medical devices industries.
-
What is the leading region in the amebocyte lysate market?
North America is the leading region in the amebocyte lysate market.